Valneva SE ADR VALN

Morningstar Rating
$5.57 −0.09 (1.50%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VALN is trading at a LOCK|V@r$$ premium.
Price
$5.57
Fair Value
LOCK|.^P&W@T
Uncertainty
LOCK|b% !M%Z
1-Star Price
LOCK|.WC$j>>
5-Star Price
LOCK|!&lg&<
Economic Moat
LOCK|nw
Capital Allocation
—

News

Trading Information

Previous Close Price
$5.65
Day Range
$5.51–5.80
52-Week Range
$4.75–12.18
Bid/Ask
$3.87 / $6.50
Shares Outstanding
95.13M
Market Cap
$529.38M
Volume/Avg
5,982 / 27,722

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2.98
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
674

Valuation

Metric
VALN
Price/Earnings (Normalized)
—
Price/Book Value
13.38
Price/Sales
2.98
Price/Cash Flow
—
Price/Earnings
VALN

Financial Strength

Metric
VALN
Quick Ratio
1.33
Current Ratio
2.16
Interest Coverage
−2.90
Quick Ratio
VALN

Profitability

Metric
VALN
Return on Assets (Normalized)
−37.82%
Return on Equity (Normalized)
−153.90%
Return on Invested Capital (Normalized)
−39.36%
Return on Assets
VALN

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|CT?$XTLOCK|Dc%>z$135B
Regeneron Pharmaceuticals Inc
REGN
LOCK|cHw&jTLOCK|!jDQ$99B
Moderna Inc
MRNA
LOCK|@JD@<!LOCK|G@J$84B
argenx SE ADR
ARGX
LOCK|l&%?@gLOCK|Q#$59B
BeOne Medicines Ltd ADR
ONC
LOCK|j@&HR?zLOCK|m<P$48B
Royalty Pharma PLC Class A
RPRX
LOCK|cTm#kPfLOCK|Mp<!$31B
Incyte Corp
INCY
LOCK|?!<q<?LOCK|!&C$24B
BioNTech SE ADR
BNTX
LOCK|g>G&v>CLOCK|S#D$21B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|xX>?jKSLOCK|$^ZX$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|N%mMVgLOCK|www$15B

Sponsor Center